GlobeNewswire

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
12/08/2026
-- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a [...]
FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
12/08/2026
Investigational AI-powered multiomic test is being developed for adults ages 50-80 at high risk who are not currently participating in guideline-recommended lung cancer screening BRISBANE, Calif., Aug. 12, 2026 (GLOBE [...]
Olympia Pharmaceuticals Advances Longevity Offerings With Advanced Injectable CoQ10 Formulation
12/08/2026
Formulated in an advanced MCT oil base, the new 20 mg/mL formulation offers healthcare providers an effective, patient-friendly option for mitochondrial and cardiovascular health ORLANDO, Fla., Aug. 12, 2026 (GLOBE [...]
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
12/08/2026
Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge Highlights Company’s investigational drug Ampligen® (rintatolimod) and its [...]
ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions
12/08/2026
TYLER, Texas, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that it has entered into a securities [...]
Biomimetic Innovations Ltd announces First-in-Human application of OsStic™ Injectable Synthetic Bone Void Filler
12/08/2026
SHANNON, Ireland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Biomimetic Innovations Ltd, an affiliate of PBC Biomed - an Irish medical device company specialising in biomimetic materials, today announced the successful First-in- [...]
Mapi Pharma Announces Initial Phase I/IIa Clinical Results Supporting Continued Development of Once-Monthly Cariprazine Depot
12/08/2026
NESS ZIONA, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today announced initial [...]
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
12/08/2026
Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 [...]
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
12/08/2026
BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases [...]
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
12/08/2026
COPENHAGEN, Denmark, Aug. 12, 2026 (GLOBE NEWSWIRE) -- SNIPR today announced the publication of a peer-reviewed expanded access case report in Clinical Infectious Diseases https://doi.org/10.1093/cid/ciag446 describing [...]
Rakovina Therapeutics Announces Closing of First Tranche, Upsize and Extension of Non-Brokered Private Placement
12/08/2026
Expanded financing broadens Rakovina’s strategic investor base and reinforces confidence in its AI-powered oncology platform VANCOUVER, British Columbia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX [...]
BioPorto A/S to host an investor webcast on the results for the first half of 2026
12/08/2026
BioPorto A/S to host an investor webcast on the results for the first half of 2026 COPENHAGEN, DENMARK, August 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), announced today that CEO [...]
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
12/08/2026
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic [...]
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
12/08/2026
GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference ( [...]
Anteris Technologies Announces Results for the Second Quarter of 2026
12/08/2026
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, [...]
The Rehab Podcast Refocuses on Benzodiazepine Tapering, Protracted Withdrawal, and BIND
11/08/2026
The Mental Health News Radio Network program, hosted by Mark Leeds, D.O., is turning toward benzodiazepine-related conditions and deprescribing, and is opening guest booking to clinicians, researchers, and people with [...]
COSCIENS Biopharma Inc. Reports Q2 2026 Results
11/08/2026
TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) (“ COSCIENS ” or the “ Company ”) today reported its financial and operating results for the second quarter ended [...]
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
11/08/2026
New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late-stage drug [...]
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
11/08/2026
Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps Remains in active discussions with the FDA to support resolution of the [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum